Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
about
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesIi-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionCD8 T cell recall responses are regulated by the tissue tropism of the memory cell and pathogen.Induced Regulatory T Cells Superimpose Their Suppressive Capacity with Effector T Cells in Lymph Nodes via Antigen-Specific S1p1-Dependent Egress Blockage.NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.Effective cancer vaccine platform based on attenuated salmonella and a type III secretion systemExpression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study.Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapyTumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentationTumor-infiltrating T lymphocytes: friends or foes?Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsIntratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.The tumor-draining lymph node as an immune-privileged site.Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.Indoleamine 2,3-dioxygenase and tumor-induced toleranceTargeting tumors with LIGHT to generate metastasis-clearing immunityManipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.Carboxymethylpachymaran enhances immunologic function of dendritic cells cultured in two kinds of hepatoma carcinoma cell line's supernatant via nuclear factor κ B/Rel pathway.GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver.Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus.
P2860
Q24678759-4A325E0C-0F33-45BC-A0E0-3E1E66475D89Q30359230-E4A607B5-74BE-4D61-82CF-CE814226481DQ33486534-3A809E49-E288-44D7-8A98-EAD9D409DFB9Q33760409-E2336796-DB8A-40AA-BB87-8202DA5E83CEQ33770196-62E44C57-F515-4F8F-A772-30E37347704FQ33946628-4C73175E-17D7-45C2-9719-39AD2F6D44CEQ34243372-E1F26815-8BD5-48F4-9F4F-687021ADFD1CQ34357503-146AE54E-BBB6-4B50-894E-A5D6C06654C3Q34438443-3F85121E-DE09-4A2C-A71F-C4819B20E427Q35835489-3F7DC526-EF32-4D89-B7FD-45FDC964E6E3Q35852726-60B339E0-E354-4AB9-97CA-DAB10F349808Q36328394-8B86C3E1-0530-419D-B1CF-A2CAD038B89DQ36373352-78943116-7DCD-4BFF-AE27-16D116F28875Q36381918-AB2444E0-110F-4E84-9B54-AB6245E9919CQ36399737-06E702B7-E1A6-4780-ADC0-722742A7274BQ36402716-46E1C69E-F6C7-4C55-A6A7-5B30E0A0534CQ36404025-E36985F0-34EF-445F-A273-7B38DC74FAB3Q36569004-ADA3F88F-5556-432A-9010-08142C99BC73Q36593753-DEBFFB83-84AE-451F-A5ED-7C97DC2DE064Q36663505-4221C826-799B-4704-A535-BC32BD04FDFFQ36809762-2E426382-553D-4E1E-99BB-952E4971E230Q37175025-D6C7A5BB-D45A-4C07-859D-42BD6207E71FQ37522460-A62386F6-8926-4E13-9F28-1C1433BDD779Q38266149-159933DC-20A4-4CCE-B08E-6990CEDC0904Q38819190-68CDD5A1-6BF1-4206-BD3D-35AA9C29A0FCQ39370993-B7E36696-1862-43D8-B74D-DDC59BE949D2Q41625041-AADDDB7A-C1C9-48EF-9CB9-815C3E5AD9E2Q42429630-788E5387-6669-42E6-8AF1-0D93A1951B4FQ42724764-5B5728F7-C5AF-4D8D-93AB-52C5449517E7
P2860
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@ast
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@en
type
label
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@ast
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@en
altLabel
Complementary Role of CD4+T Ce ...... f Tumor Antigen to CD8+T Cells
@en
prefLabel
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@ast
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells.
@en
P2093
P2860
P356
P1476
Complementary role of CD4+ T c ...... tumor antigen to CD8+ T cells
@en
P2093
Hans Schreiber
Michael T Spiotto
Youjin Lee
P2860
P304
P356
10.1084/JEM.20021804
P407
P50
P577
2003-04-14T00:00:00Z